Truist Securities Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $140

Neurocrine Biosciences, Inc. 0.00% Pre

Neurocrine Biosciences, Inc.

NBIX

129.86

129.86

0.00%

0.00% Pre
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ: NBIX) with a Buy and lowers the price target from $169 to $140.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via